279 related articles for article (PubMed ID: 27239884)
1. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: Teaching Drug Marketers How to Inform Better or Spin Better? Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Doran E
Int J Health Policy Manag; 2016 Feb; 5(5):333-5. PubMed ID: 27239884
[TBL] [Abstract][Full Text] [Related]
2. The Tip of the Iceberg of Misleading Online Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Mintzes B
Int J Health Policy Manag; 2016 Feb; 5(5):329-31. PubMed ID: 27239883
[TBL] [Abstract][Full Text] [Related]
3. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
Kim H
Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
[TBL] [Abstract][Full Text] [Related]
4. The Conundrum of Online Prescription Drug Promotion Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Wanasika I
Int J Health Policy Manag; 2016 Mar; 5(6):391-2. PubMed ID: 27285519
[TBL] [Abstract][Full Text] [Related]
5. Considering the Future of Pharmaceutical Promotions in Social Media Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Carpentier FR
Int J Health Policy Manag; 2016 Feb; 5(4):283-5. PubMed ID: 27239874
[TBL] [Abstract][Full Text] [Related]
6. Still the Great Debate - "Fair Balance" in Direct-to-Consumer Prescription Drug Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Rollins BL
Int J Health Policy Manag; 2016 Feb; 5(4):287-8. PubMed ID: 27239875
[TBL] [Abstract][Full Text] [Related]
7. Digital Direct-to-Consumer Advertising: A Perfect Storm of Rapid Evolution and Stagnant Regulation Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Mackey TK
Int J Health Policy Manag; 2016 Feb; 5(4):271-4. PubMed ID: 27239871
[TBL] [Abstract][Full Text] [Related]
8. Future Challenges and Opportunities in Online Prescription Drug Promotion Research Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Southwell BG; Rupert DJ
Int J Health Policy Manag; 2016 Jan; 5(3):211-3. PubMed ID: 26927597
[TBL] [Abstract][Full Text] [Related]
9. Fair Balance and Adequate Provision in Direct-to-Consumer Prescription Drug Online Banner Advertisements: A Content Analysis.
Adams C
J Med Internet Res; 2016 Feb; 18(2):e33. PubMed ID: 26892749
[TBL] [Abstract][Full Text] [Related]
10. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.
Klara K; Kim J; Ross JS
J Gen Intern Med; 2018 May; 33(5):651-658. PubMed ID: 29484575
[TBL] [Abstract][Full Text] [Related]
11. The legal and ethical dimensions of direct-to-consumer advertising of prescription drugs: the case of Pfizer and Lipitor in the United States.
Koku PS
Health Mark Q; 2021; 38(1):23-34. PubMed ID: 34219606
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites.
Tyrawski J; DeAndrea DC
J Med Internet Res; 2015 Jun; 17(6):e130. PubMed ID: 26032738
[TBL] [Abstract][Full Text] [Related]
13. A survey of perceptions and attitudes about direct-to-consumer advertising of prescription drugs among college students in South Korea.
Yang YM; Lee JJ; Jeong E; Kim SY; Han MA; Choi EJ
PLoS One; 2018; 13(7):e0201108. PubMed ID: 30040833
[TBL] [Abstract][Full Text] [Related]
14. Direct-to-consumer advertising of prescription drugs.
Frosch DL; Grande D
LDI Issue Brief; 2010; 15(3):1-4. PubMed ID: 20469541
[TBL] [Abstract][Full Text] [Related]
15. Correction of misleading information in prescription drug television advertising: The roles of advertisement similarity and time delay.
Aikin KJ; Southwell BG; Paquin RS; Rupert DJ; O'Donoghue AC; Betts KR; Lee PK
Res Social Adm Pharm; 2017; 13(2):378-388. PubMed ID: 27178746
[TBL] [Abstract][Full Text] [Related]
16. Promotion of prescription drugs to consumers.
Rosenthal MB; Berndt ER; Donohue JM; Frank RG; Epstein AM
N Engl J Med; 2002 Feb; 346(7):498-505. PubMed ID: 11844852
[TBL] [Abstract][Full Text] [Related]
17. Learning to Spot False or Misleading Prescription Drug Promotion.
Aschenbrenner DS
Am J Nurs; 2020 Oct; 120(10):23. PubMed ID: 32976147
[No Abstract] [Full Text] [Related]
18. Can direct-to-consumer advertising of prescription drugs be effectively regulated?
Lexchin J; Menkes DB
N Z Med J; 2019 Jun; 132(1496):59-65. PubMed ID: 31170134
[TBL] [Abstract][Full Text] [Related]
19. The rise of digital direct-to-consumer advertising?: Comparison of direct-to-consumer advertising expenditure trends from publicly available data sources and global policy implications.
Mackey TK; Cuomo RE; Liang BA
BMC Health Serv Res; 2015 Jun; 15():236. PubMed ID: 26084705
[TBL] [Abstract][Full Text] [Related]
20. A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising.
Frosch DL; Grande D; Tarn DM; Kravitz RL
Am J Public Health; 2010 Jan; 100(1):24-32. PubMed ID: 19910354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]